MX353254B - Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2). - Google Patents

Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2).

Info

Publication number
MX353254B
MX353254B MX2014006209A MX2014006209A MX353254B MX 353254 B MX353254 B MX 353254B MX 2014006209 A MX2014006209 A MX 2014006209A MX 2014006209 A MX2014006209 A MX 2014006209A MX 353254 B MX353254 B MX 353254B
Authority
MX
Mexico
Prior art keywords
pet
lrrk2
imaging
positron emission
emission tomography
Prior art date
Application number
MX2014006209A
Other languages
English (en)
Other versions
MX2014006209A (es
Inventor
K Chan Bryan
Estrada Anthony
Kevin Sweeney Zachary
Marik Jan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2014006209A publication Critical patent/MX2014006209A/es
Publication of MX353254B publication Critical patent/MX353254B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para la formación de imágenes por tomografía de emisión de positrones (PET) de LRRK2 en el tejido de un sujeto, el método comprende: administrar un compuesto de fórmula (I), fórmula (II) o fórmula (III), o una sal farmacéuticamente aceptable del mismo al sujeto, en donde el compuesto incluye al menos un marcador de C11 o F18 sobre el mismo; permitir que el compuesto penetre en el tejido del sujeto; y tomar una imagen PET del SNC o tejido cerebral del sujeto.
MX2014006209A 2011-11-30 2012-11-28 Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2). MX353254B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565324P 2011-11-30 2011-11-30
US201261720870P 2012-10-31 2012-10-31
PCT/EP2012/073770 WO2013079496A1 (en) 2011-11-30 2012-11-28 Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2

Publications (2)

Publication Number Publication Date
MX2014006209A MX2014006209A (es) 2014-08-08
MX353254B true MX353254B (es) 2018-01-05

Family

ID=47297200

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006209A MX353254B (es) 2011-11-30 2012-11-28 Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2).

Country Status (11)

Country Link
US (1) US9139566B2 (es)
EP (1) EP2785381B1 (es)
JP (1) JP6148248B2 (es)
KR (1) KR101996699B1 (es)
CN (1) CN104093426B (es)
BR (1) BR112014012822A8 (es)
CA (1) CA2856002C (es)
ES (1) ES2580406T3 (es)
MX (1) MX353254B (es)
RU (1) RU2650641C2 (es)
WO (1) WO2013079496A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029196T2 (en) * 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
SG189043A1 (en) * 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators
AR089182A1 (es) * 2011-11-29 2014-08-06 Hoffmann La Roche Derivados de aminopirimidina como moduladores de lrrk2
EP2844658B1 (en) * 2012-05-03 2019-03-20 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
US10087186B2 (en) * 2014-01-29 2018-10-02 Glaxosmithkline Intellectual Property Development Limited Compounds as LRRK2 kinase inhibitors
ES2717757T3 (es) 2014-01-29 2019-06-25 Glaxosmithkline Ip Dev Ltd Compuestos
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
SI3472153T1 (sl) 2016-06-16 2022-01-31 Denali Therapeutics Inc. Pirimidin-2-ilamino-1H-pirazoli kot zaviralci LRRK2 za uporabo pri zdravljenju nevrodegenerativnih motenj
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
CN107827870B (zh) * 2017-10-24 2019-11-08 江苏仁明生物科技有限公司 一种正电子药物[18f]fpmmp及其制备方法与中间体
US11834438B2 (en) 2017-12-20 2023-12-05 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
AU2020274011B2 (en) 2019-05-10 2024-02-15 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
RS65019B1 (sr) 2019-05-10 2024-01-31 Deciphera Pharmaceuticals Llc Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primene
CN119241444A (zh) 2019-06-17 2025-01-03 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
CN111646978B (zh) * 2020-06-11 2021-12-21 浙江大学 N2-取代烷氧芳环-2-氨基嘧啶类衍生物及应用
CN111732548B (zh) * 2020-06-11 2022-06-17 浙江大学 N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途
WO2022084210A1 (en) 2020-10-20 2022-04-28 F. Hoffmann-La Roche Ag Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4448763A (en) * 1980-11-10 1984-05-15 The University Of Kentucky Research Foundation Alteration of gallium biodistribution using indium complexes for enhanced early imaging
US20080131937A1 (en) 2006-06-22 2008-06-05 Applera Corporation Conversion of Target Specific Amplification to Universal Sequencing
WO2008024830A2 (en) * 2006-08-23 2008-02-28 Board Of Regents, The University Of Texas System Radiohaloimatinibs and methods of their synthesis and use in pet imaging of cancers
WO2009127642A2 (en) * 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
AR074209A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina utiles para el tratamiento del cancer
US8778939B2 (en) 2009-09-29 2014-07-15 Glaxo Group Limited Compounds
HUE029196T2 (en) * 2010-06-04 2017-02-28 Hoffmann La Roche Aminoprimidine derivatives as LRRK2 modulators
SG189043A1 (en) * 2010-11-10 2013-05-31 Hoffmann La Roche Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Also Published As

Publication number Publication date
WO2013079496A1 (en) 2013-06-06
JP6148248B2 (ja) 2017-06-14
US20130156700A1 (en) 2013-06-20
HK1197192A1 (en) 2015-01-09
BR112014012822A2 (pt) 2017-06-13
EP2785381B1 (en) 2016-05-18
KR101996699B1 (ko) 2019-07-04
CA2856002C (en) 2020-10-13
ES2580406T3 (es) 2016-08-23
RU2014125211A (ru) 2016-01-27
EP2785381A1 (en) 2014-10-08
US9139566B2 (en) 2015-09-22
JP2015500216A (ja) 2015-01-05
RU2650641C2 (ru) 2018-04-16
MX2014006209A (es) 2014-08-08
CA2856002A1 (en) 2013-06-06
BR112014012822A8 (pt) 2017-07-11
CN104093426B (zh) 2019-06-28
KR20140097470A (ko) 2014-08-06
CN104093426A (zh) 2014-10-08

Similar Documents

Publication Publication Date Title
MX2014006209A (es) Radioligandos marcados con fluor-18 y carbono-11 para la formacion de imagenes por tomografia de emision de positrones para proteina cinasa 2 de repeticion rica en leucina (lrrk2).
FR2972915B1 (fr) Systeme d'imagerie medicale multiplan
EA033067B1 (ru) Способ лечения метаболических расстройств у пациента, имеющего противопоказание к назначению бигуанидного соединения
BR112014032558A2 (pt) aparelho e métodos de autoalinhamento para coletar fardos
UA114726C2 (uk) 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів
ZA201206264B (en) Crystalline forms for 5-amino-2,3-dihydrophathalazine-1,4-dione sodium salt,pharmaceutical preparations containing the same and method for the production of said forms
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
IN2014CN03470A (es)
GT201400022A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
MX2013007699A (es) Solucion de eluyente.
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
MX360640B (es) Diagnosis e imagenologia de cancer.
SG11201400223SA (en) Method for diagnosing alzheimer's disease (ad)
MX2013012793A (es) Aminoacidos radiomarcados para imagen de diagnostico.
WO2015153772A3 (en) Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography
IL220851A0 (en) Method for preparing tetrazole methanesulfonic acid salts, and compounds used in same
FR2967520B1 (fr) Procede de traitements d'images radiologiques d'un patient
EA201391265A1 (ru) Амиды индолкарбоновых и бензимидазолкарбоновых кислот в качестве инсектицидов и акарицидов
IL229607B (en) A method for diagnosing Gaucher's disease
IL225855A0 (en) Pet tracer precursor compounds, compositions comprising the same, processes for preparing the same and uses thereof
WO2012151464A3 (en) Use of radiographic contrast agents for detecting dental caries
MX353991B (es) Agonista del receptor de 5-ht4 como agente procinetico.
MX342465B (es) Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.
IN2014DN06805A (es)
MX2013007188A (es) Simplificacion de proceso para compuesto precursor.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GENENTECH, INC.

FG Grant or registration